Press Releases

August 5, 2024 Lupin Announces Successful Completion of Phase 3 Trials for Lucentis® Biosimilar

August 5, 2024 Lupin Receives Approval from U.S. FDA for Prednisolone Acetate Ophthalmic Suspension USP

July 31, 2024 Lupin Receives Approval from U.S. FDA for Emtricitabine and Tenofovir Alafenamide Tablets

July 19, 2024 Lupin’s Alliance Partner ForDoz Receives U.S. FDA Approval for Doxorubicin Hydrochloride Liposome Injection

July 18, 2024 Lupin and Huons Sign License and Supply Agreement for Commercialization of Cyclosporine Ophthalmic Nanoemulsionin Mexico

July 16, 2024 Lupin Receives Tentative Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets

July 12, 2024 Lupin Receives Approval from U.S. FDA for Topiramate Extended-Release Capsules

July 12, 2024 Lupin Receives EIR from U.S. FDA for its Dabhasa Facility

July 9, 2024 Lupin Receives Tentative Approval from U.S. FDA for Empagliflozin, Linagliptin and Metformin Hydrochloride Extended-Release Tablets